KeraNetics specializes in developing innovative keratin-based products aimed at managing skin injuries, particularly those resulting from radiation therapy. Their flagship product, KeraStat® Cream, is FDA-cleared for the treatment of radiation dermatitis, a common side effect experienced by cancer patients undergoing radiotherapy. This cream utilizes the properties of keratin proteins to support the healing of dry and moderately exuding partial thickness skin wounds. KeraStat® Cream is designed to alleviate symptoms such as redness, soreness, and itching, thereby improving the quality of life for patients undergoing cancer treatment.

In addition to KeraStat® Cream, KeraNetics also offers KeraStat® Gel, a sterile hydrogel wound dressing that serves as a protective covering for various partial thickness dermal wounds. Both products are part of KeraNetics' commitment to providing effective solutions for skin injuries, particularly those associated with thermal burns and soft tissue defects. The company’s focus on harnessing keratin proteins reflects a dedication to advancing wound care technologies that empower healthcare providers and enhance patient outcomes.

United States

KeraNetics is the global leader in keratin science, purified, human-derived keratin manufacture, research and development for healthier wound healing
KeraNetics provides physicians with new options to help patients by exploiting the properties of purified, human-derived keratin. 

KeraStat® Cream: Better management of radiation dermatitis (RD).  

KeraStat® Cream harnesses the power of keratin proteins to support the management of dry, light, and moderately exuding partial thickness skin wounds such as radiation dermatitis resulting from a fractionated radiotherapy regimen.  FDA cleared and available in 1 oz. and 5 mL tubes. Rx only.


KeraNetics

Company Details